We serve Chemical Name:4-Bromo-3,5-dichlorobenzoic acid CAS:117738-75-7 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:4-Bromo-3,5-dichlorobenzoic acid
CAS.NO:117738-75-7
Synonyms:4-Brom-3,5-dichlor-benzoesaeure;4-bromo-3,5-dichloro-benzoic acid
Molecular Formula:C7H3BrCl2O2
Molecular Weight:269.90800
HS Code:2916399090
Physical and Chemical Properties:
Melting point:N/A
Boiling point:N/A
Density:N/A
Index of Refraction:
PSA:37.30000
Exact Mass:267.86900
LogP:3.45410
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:
Contact us for information like 4-Brom-3,5-dichlor-benzoesaeure chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,4-bromo-3,5-dichloro-benzoic acid physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,4-bromo-3,5-dichloro-benzoic acid Use and application,4-bromo-3,5-dichloro-benzoic acid technical grade,usp/ep/jp grade.
Related News: Characteristic APIs represented by cardiovascular, antiviral, antitumor and other categories are targeted at generic APIs with patent expiring original research drugs, which have high scientific and technological content and rich profits. They have developed in China in the past decade. The more active API segment has contributed to the rise of Huahai Pharmaceutical, Chuangnuo Pharmaceutical, and Jiangbei Pharmaceutical. 4-Bromo-3,5-dichlorobenzoic acid manufacturer Cases recorded in Thailand, Taiwan, Germany, Vietnam, Japan, France and the United States involved patients who had not been to China. 4-Bromo-3,5-dichlorobenzoic acid supplier The patient, who arrived from Wuhan, is ��stable and under medical care,�� the ministry said in a statement, adding there is ��no cause for concern�� for the public. 4-Bromo-3,5-dichlorobenzoic acid vendor Characteristic APIs represented by cardiovascular, antiviral, antitumor and other categories are targeted at generic APIs with patent expiring original research drugs, which have high scientific and technological content and rich profits. They have developed in China in the past decade. The more active API segment has contributed to the rise of Huahai Pharmaceutical, Chuangnuo Pharmaceutical, and Jiangbei Pharmaceutical. 4-Bromo-3,5-dichlorobenzoic acid factory Taking Minuo Huawei as an example, in 2016, the capacity utilization rate and production-sales ratio of its multiple drug substance varieties reached more than 90%. Therefore, domestic API companies have expanded their production capacity in recent years to meet the growing demand for APIs.
